These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 16293234)

  • 1. Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme.
    Mailliet F; Ferry G; Vella F; Berger S; Cogé F; Chomarat P; Mallet C; Guénin SP; Guillaumet G; Viaud-Massuard MC; Yous S; Delagrange P; Boutin JA
    Biochem Pharmacol; 2005 Dec; 71(1-2):74-88. PubMed ID: 16293234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT3.
    Mailliet F; Ferry G; Vella F; Thiam K; Delagrange P; Boutin JA
    FEBS Lett; 2004 Dec; 578(1-2):116-20. PubMed ID: 15581627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies of the melatonin binding site location onto quinone reductase 2 by directed mutagenesis.
    Boutin JA; Saunier C; Guenin SP; Berger S; Moulharat N; Gohier A; Delagrange P; Cogé F; Ferry G
    Arch Biochem Biophys; 2008 Sep; 477(1):12-9. PubMed ID: 18502195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MT3/QR2 melatonin binding site does not use melatonin as a substrate or a co-substrate.
    Boutin JA; Marcheteau E; Hennig P; Moulharat N; Berger S; Delagrange P; Bouchet JP; Ferry G
    J Pineal Res; 2008 Nov; 45(4):524-31. PubMed ID: 18826489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New ligands at the melatonin binding site MT(3).
    Boussard MF; Truche S; Rousseau-Rojas A; Briss S; Descamps S; Droual M; Wierzbicki M; Ferry G; Audinot V; Delagrange P; Boutin JA
    Eur J Med Chem; 2006 Mar; 41(3):306-20. PubMed ID: 16414149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2 .
    Nosjean O; Nicolas JP; Klupsch F; Delagrange P; Canet E; Boutin JA
    Biochem Pharmacol; 2001 Jun; 61(11):1369-79. PubMed ID: 11331072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinone reductase 2 and antidepressant effect of melatonin derivatives.
    Oxenkrug GF; Bachurin SO; Prakhie IV; Zefirov NS
    Ann N Y Acad Sci; 2010 Jun; 1199():121-4. PubMed ID: 20633117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2.
    Calamini B; Santarsiero BD; Boutin JA; Mesecar AD
    Biochem J; 2008 Jul; 413(1):81-91. PubMed ID: 18254726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Old and new inhibitors of quinone reductase 2.
    Ferry G; Hecht S; Berger S; Moulharat N; Coge F; Guillaumet G; Leclerc V; Yous S; Delagrange P; Boutin JA
    Chem Biol Interact; 2010 Jul; 186(2):103-9. PubMed ID: 20399199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NRH:quinone reductase 2: an enzyme of surprises and mysteries.
    Vella F; Ferry G; Delagrange P; Boutin JA
    Biochem Pharmacol; 2005 Dec; 71(1-2):1-12. PubMed ID: 16253210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance.
    Tan DX; Manchester LC; Terron MP; Flores LJ; Tamura H; Reiter RJ
    J Pineal Res; 2007 Nov; 43(4):317-20. PubMed ID: 17910598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3.
    Leclerc V; Ettaoussi M; Rami M; Farce A; Boutin JA; Delagrange P; Caignard DH; Renard P; Berthelot P; Yous S
    Eur J Med Chem; 2011 May; 46(5):1622-9. PubMed ID: 21377769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel quantitative structure-activity relationship method to predict the affinities of MT3 melatonin binding site.
    Du H; Wang J; Zhang X; Hu Z
    Eur J Med Chem; 2008 Dec; 43(12):2861-9. PubMed ID: 18400335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of melatonin ligands.
    Delagrange P; Boutin JA
    Chronobiol Int; 2006; 23(1-2):413-8. PubMed ID: 16687314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. X-ray structural studies of quinone reductase 2 nanomolar range inhibitors.
    Pegan SD; Sturdy M; Ferry G; Delagrange P; Boutin JA; Mesecar AD
    Protein Sci; 2011 Jul; 20(7):1182-95. PubMed ID: 21538647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of 2-[125I]iodomelatonin binding sites in Syrian hamster peripheral organs.
    Paul P; Lahaye C; Delagrange P; Nicolas JP; Canet E; Boutin JA
    J Pharmacol Exp Ther; 1999 Jul; 290(1):334-40. PubMed ID: 10381796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines.
    Kwiek JJ; Haystead TA; Rudolph J
    Biochemistry; 2004 Apr; 43(15):4538-47. PubMed ID: 15078100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into the redox cycle of human quinone reductase 2.
    Reybier K; Perio P; Ferry G; Bouajila J; Delagrange P; Boutin JA; Nepveu F
    Free Radic Res; 2011 Oct; 45(10):1184-95. PubMed ID: 21762045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Melatonin binding site MT3 is QR2: state of the art].
    Boutin JA
    J Soc Biol; 2007; 201(1):97-103. PubMed ID: 17762829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An unexpected effect of 5-MCA-NAT in chick retinal development.
    Sampaio Lde F
    Int J Dev Neurosci; 2009 Oct; 27(6):511-5. PubMed ID: 19596433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.